Trethera Collaborates with MGH on ALS Clinical Trial for TRE-515

The biopharmaceutical company will evaluate its investigational therapy in up to six patients with advanced amyotrophic lateral sclerosis.

Mar. 31, 2026 at 2:22pm

Got story updates? Submit your updates here. ›

An extreme close-up X-ray photograph revealing the intricate internal structure of a human nerve cell, conveying the complex biological mechanisms underlying ALS.A novel investigational therapy aims to modulate inflammation and potentially stabilize disease progression in patients with advanced ALS.Boston Today

Trethera Corporation, a clinical-stage biopharmaceutical company, has announced a collaboration with Massachusetts General Hospital (MGH) to evaluate its investigational therapy TRE-515 in up to six patients with advanced amyotrophic lateral sclerosis (ALS) under the FDA Expanded Access program. TRE-515 inhibits deoxycytidine kinase, an enzyme involved in inflammatory signaling, and emerging evidence suggests inflammation may contribute to ALS.

Why it matters

Therapeutic options for ALS remain limited, so exploring novel approaches like TRE-515 is crucial for patients facing this devastating disease. The collaboration with the renowned ALS research center at MGH could help inform the biological activity of TRE-515 and guide future clinical development.

The details

During the collaboration, up to six patients with advanced ALS will be enrolled in a trial conducted by MGH. The trial will evaluate the safety and tolerability of TRE-515 while tracking disease trajectory over time and collecting pharmacodynamic and ALS disease biomarkers. This integrated clinical and biomarker approach may help guide patient selection and serve as a platform for larger clinical trials.

  • The collaboration was announced on March 31, 2026.

The players

Trethera Corporation

A clinical-stage biopharmaceutical company developing first-in-class therapies for cancer, autoimmune, and neuroimmune diseases.

Massachusetts General Hospital (MGH)

The original and largest teaching hospital of Harvard Medical School, internationally recognized as a leading ALS research center.

Dr. Merit Cudkowicz

Executive Director of the Massachusetts General Brigham Neuroscience Institute and principal investigator for the trial.

Dr. Lawrence Steinman

Member of Trethera's Scientific Advisory Board and Professor of Neurology at Stanford University.

Dr. Ken Schultz

Trethera Chairman and CEO.

Got photos? Submit your photos here. ›

What they’re saying

“This collaboration with MGH follows our encouraging ALS clinical findings last year and is an important step in expanding our clinical efforts to understand and treat this devastating disease.”

— Dr. Ken Schultz, Trethera Chairman and CEO

“Therapeutic options for ALS remain limited, and there is a continuing need to explore novel approaches for patients facing this serious disease.”

— Dr. Merit Cudkowicz, Executive Director of the Massachusetts General Brigham Neuroscience Institute

“We are particularly encouraged by the potential of treating ALS with TRE-515 given its ability to selectively modulate inflammation and its favorable safety profile observed to date.”

— Dr. Lawrence Steinman, Member of Trethera's Scientific Advisory Board and Professor of Neurology at Stanford University

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This collaboration between Trethera and MGH represents a promising step forward in the search for new treatments for the devastating disease of ALS, which continues to have limited therapeutic options available. The integrated clinical and biomarker approach of the trial could help guide future patient selection and clinical development of TRE-515.